Recent approvals of six CD19‐targeted CAR‐T cell products, Kymriah, Yescarta, Tecartus, Abecma, Breyanzi and Carvykti by the US FDA for treatment of B‐cell acute lymphoblastic leukemia (B‐ALL), diffuse large B‐cell lymphoma (DLBCL), mantle cell lymphoma, relapsed or refractory multiple myeloma, and relapsed or refractory large B‐cell lymphoma are considered milestones in the field, which has created enormous interest in the scientific community.4, 5. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.